u utah

University of Utah

u utah1

Department of Pediatrics
81 N Mario Capecchi Drive Level 4
Salt Lake City, UT 84113
United States

Led by Zoe Raleigh, MD, the TrialNet team at University of Utah is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Our Team

Raleigh

Zoe Raleigh, MD

Dr. Raleigh joined the TrialNet team at the University of Utah in 2020. She is currently an Assistant Professor in the Department of Pediatrics. She has served as principal investigator for a local study evaluating pump failure in type 1 diabetes, and currently serves as either principal investigator or co-investigator for the Type 1 Diabetes TrialNet studies.

Raman

Vandana Raman, MD, MBBS

Dr. Raman joined the TrialNet team at the University of Utah in 2017. She is currently an Associate Professor in the Department of Pediatrics, as well as director of the Pediatric Endocrinology and Diabetes Fellowship program and medical director for the “DIME” (diabetes intensive management and education) clinic. She has served as the local principal investigator for several multi-center type 1 diabetes network studies through the T1D Exchange group, and currently serves as either principal investigator or co-investigator for the Type 1 Diabetes TrialNet studies

Hillarie Slater, BS RPT CBDT CCRC

Research & Densitometry Manager
Elisa Anguiano

Elisa Anguiano, RN

Study Coordinator

Jasmine Masih, BS

Clinical Study Assistant

Research Studies

Risk Screening Risk Screening for Relatives

If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More

Monitoring Monitoring

Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More

Prevention Study ATG Prevention Study (STOP-T1D)

TrialNet is testing a low dose of the immunotherapy drug anti-thymocyte globulin (ATG) to see if it can delay or prevent type 1 diabetes (T1D) in people ages 12 up to 35 who have a 50% risk of clinical diagnosis (Stage 3) within 2 years. Risk is defined by having two or more autoantibodies and abnormal blood sugar (Stage 2), plus at least one high-risk marker (based on test results). In an earlier TrialNet study for people newly diagnosed with T1D, low-dose ATG preserved insulin production and improved blood sugar control for 2 years. Details

Long Term Long-Term Follow-up

If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More